Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study

De Vita Salvatore; Quartuccio Luca; Seror Raphaele; Salvin Sara; Ravaud Philippe; Fabris Martina; Nocturne Gaetane; Gandolfo Saviana; Isola Miriam; Mariette Xavier

首页> 外文期刊>Rheumatology >Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study

【24h】

Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study

机译：贝利木单抗在原发性干燥综合征中使用12个月的疗效和安全性：BELISS开放标签II期研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective. To report the efficacy and safety of long-term treatment of SS with belimumab, targeting the B-cell-activating factor.

机译：目的。报告针对以B细胞活化因子为靶标的贝利木单抗长期治疗SS的疗效和安全性。

著录项

来源
《Rheumatology》 |2015年第12期|共8页
作者
De Vita Salvatore; Quartuccio Luca; Seror Raphaele; Salvin Sara; Ravaud Philippe; Fabris Martina; Nocturne Gaetane; Gandolfo Saviana; Isola Miriam; Mariette Xavier;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
belimumab; primary Sjogren's syndrome; trial;

机译：贝利木单抗;原发性干燥综合征;试验;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study [J] . De Vita Salvatore, Quartuccio Luca, Seror Raphaele, Rheumatology . 2015,第12期

机译：贝利木单抗在原发性干燥综合征中使用12个月的疗效和安全性：BELISS开放标签II期研究
2. Efficacy and Safety of Belimumab Given for 12 Months in Primary Sjogren's Syndrome: The Beliss Open-Label Phase II Study [J] . De Vita Salvatore, Quartuccio Luca, Seror Raphaele, Scandinavian journal of immunology. . 2015,第5期

机译：贝利单抗治疗原发性干燥综合征的疗效和安全性为期12个月：Beliss Open-Label II期研究
3. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study [J] . Mariette Xavier, Seror Raphaele, Quartuccio Luca, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2015,第3期

机译：贝利木单抗在原发性干燥综合征中的疗效和安全性：BELISS开放标签II期研究的结果
4. An open-label, multicenter, randomized,comparative, safety, efficacy, cycle control,and quality of life study of CTR 25, Alesse ,and Ortho Tri-Cyclen [C] . Victoria Davis, Brian Hauck, Sheila Dunn, World Congress on Fertility and Sterility . 2004

机译：开放标签，多中心，随机，比较，安全，疗效，循环控制和CTR 25，Alesse和Ortho Tri-Cyclen的生命研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A 6-month open-label extension study of the safety and efficacy ofsubcutaneous belimumab in patients with systemic lupuserythematosus [O] . A Doria, D Bass, A Schwarting, -1

机译：为期6个月的开放标签扩展研究研究了该药的安全性和有效性全身性狼疮患者皮下贝利木单抗红斑
7. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study [O] . Salvatore De Vita, Luca Quartuccio, Raphaèle Seror, 2015

机译：Belimumab的疗效和安全在原代Sjögren综合征中给出12个月：Beliss Open-Label II研究

Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study

摘要

著录项

相似文献

相关主题

期刊订阅